Claus Christiansen

Research interests

Publications

• Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis

  JAMA · 2016 · 10.1001/jama.2016.11136

• Whole‐genome sequencing identifies EN1 as a determinant of bone density and fracture

  Nature · 2015 · https://doi.org/10.1038/nature14878

• A Meta-Analysis of the Association of Fracture Risk and Body Mass Index in Women

  Journal of Bone and Mineral Research · 2013 · 10.1002/jbmr.2017

• Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture

  Nature Genetics · 2012 · https://doi.org/10.1038/ng.2249

• Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

  New England Journal of Medicine · 2009 · https://doi.org/10.1056/nejmoa0809493

• Efficacy of Bazedoxifene in Reducing New Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis: Results From a 3-Year, Randomized, Placebo-, and Active-Controlled Clinical Trial

  Journal of Bone and Mineral Research · 2008 · 10.1359/jbmr.080710

• Multiple Genetic Loci for Bone Mineral Density and Fractures

  New England Journal of Medicine · 2008 · 10.1056/nejmoa0801197

• Refining the impact of TCF7L2 gene variants on type 2 diabetes and adaptive evolution

  Nature Genetics · 2007 · 10.1038/ng1960

• Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes

  Nature Genetics · 2007 · 10.1038/ng2062

• The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women

  Osteoporosis International · 2007 · https://doi.org/10.1007/s00198-007-0343-y

• A variant in CDKAL1 influences insulin response and risk of type 2 diabetes

  Nature Genetics · 2007 · https://doi.org/10.1038/ng2043

• Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes

  Nature Genetics · 2006 · 10.1038/ng1732

• Relationship Between Osteoporosis and Cardiovascular Disease in Postmenopausal Women

  Journal of Bone and Mineral Research · 2005 · 10.1359/jbmr.050711

• Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis

  Journal of Bone and Mineral Research · 2004 · 10.1359/jbmr.040325

• Incorporation and distribution of strontium in bone

  Bone · 2001 · 10.1016/s8756-3282(01)00419-7

• Low Body Mass Index Is an Important Risk Factor for Low Bone Mass and Increased Bone Loss in Early Postmenopausal Women

  Journal of Bone and Mineral Research · 1999 · 10.1359/jbmr.1999.14.9.1622

• Prevention of Bone Loss with Alendronate in Postmenopausal Women under 60 Years of Age

  New England Journal of Medicine · 1998 · 10.1056/nejm199802193380801

• Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal Women

  New England Journal of Medicine · 1997 · 10.1056/nejm199712043372301

• The diagnosis of osteoporosis

  Journal of Bone and Mineral Research · 1994 · 10.1002/jbmr.5650090802

• Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study.

  BMJ · 1992 · 10.1136/bmj.305.6853.556

• Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 year study.

  BMJ · 1991 · 10.1136/bmj.303.6808.961

• Postmenopausal hormone replacement therapy prevents central distribution of body fat after menopause

  Metabolism · 1991 · 10.1016/0026-0495(91)90037-w

• Does Calcium Supplementation Prevent Postmenopausal Bone Loss?

  New England Journal of Medicine · 1987 · 10.1056/nejm198701223160401

• BONE MASS IN POSTMENOPAUSAL WOMEN AFTER WITHDRAWAL OF OESTROGEN/GESTAGEN REPLACEMENT THERAPY

  The Lancet · 1981 · 10.1016/s0140-6736(81)91848-1

• Prevention of early postmenopausal bone loss: controlled 2‐year study in 315 normal females

  European Journal of Clinical Investigation · 1980 · 10.1111/j.1365-2362.1980.tb00033.x

Current projects

No projects listed.